the staff of the Ridgewood blog
Continue reading Oral Antivirals Could Transform the Treatment of COVID-19
the staff of the Ridgewood blog
Continue reading Oral Antivirals Could Transform the Treatment of COVID-19
the staff of the Ridgewood blog
NEW YORK NY, Pfizer Inc. (NYSE: PFE) today announced final results from an analysis of all 2,246 adults enrolled in its Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) trial of its novel COVID-19 oral antiviral candidate PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). These results were consistent with the interim analysis announced in November 2021, showing PAXLOVID significantly reduced the risk of hospitalization or death for any cause by 89% compared to placebo in non-hospitalized, high-risk adult patients with COVID-19 treated within three days of symptom onset. In a secondary endpoint, PAXLOVID reduced the risk of hospitalization or death for any cause by 88% compared to placebo in patients treated within five days of symptom onset, an increase from the 85% observed in the interim analysis. The EPIC-HR data have been shared with the U.S. Food and Drug Administration (FDA) as part of an ongoing rolling submission for Emergency Use Authorization (EUA).
Continue reading Pfizer says Covid-19 Pill Close To 90% effective
the staff of the Ridgewood blog
Ridgewood NJ, Pfizer requested emergency authorization for its antiviral oral COVID-19 treatment on Tuesday after a study found the pills dramatically reduced the risk of hospitalization.